Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
about
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaHaemostatic drug therapies for acute spontaneous intracerebral haemorrhageRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaHaemostatic drug therapies for acute primary intracerebral haemorrhageIntracerebral Hemorrhage: Perihemorrhagic Edema and Secondary Hematoma Expansion: From Bench Work to Ongoing ControversiesWhat's new in stroke prevention and treatmentMinimally invasive evacuation of spontaneous intracerebral hemorrhage using sonothrombolysisThe Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.Performance characteristics of methods for quantifying spontaneous intracerebral haemorrhage: data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial.Optimal management of an aneurysmal subarachnoid hemorrhage in a patient with known factor XI deficiency: a case report.Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indicationsSmall intracerebral haemorrhages are associated with less haematoma expansion and better outcomes.The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors.Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysisOff-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settingsRecombinant factor VIIa in the treatment of non-hemophiliac bleeding.Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage.Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke.The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Recombinant activated factor VIIa and hemostasis in critical care: a focus on traumaRecombinant activated factor VII and the anaesthetist.The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.Management of bleeding emergencies: when to use recombinant activated factor VII.Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: the spot sign score.The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework.The societal costs of intracerebral hemorrhage in Spain.Recombinant-activated coagulation factor VIIa (NovoSeven): current development.Advances in hemorrhagic stroke therapy: conventional and novel approaches.Management of thrombolysis-associated symptomatic intracerebral hemorrhage.Treatment and prevention of spontaneous intracerebral hemorrhage: comparison of EUSI and AHA/ASA recommendations.Hemostatic therapy for the treatment of intracranial hemorrhage.Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials.The effect of activated factor VII for intracerebral hemorrhage beyond 3 hours versus within 3 hoursHemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.Intracerebral hemorrhage: a review of coagulation function.Neutrophil-Lymphocyte Ratio and Perihematomal Edema Growth in Intracerebral Hemorrhage.Peri-Hemorrhagic Edema and Secondary Hematoma Expansion after Intracerebral Hemorrhage: From Benchwork to Practical Aspects.
P2860
Q24201292-E2898E51-2C45-41F1-AC8D-7010408C8F1FQ24236583-2E678CA6-2977-4662-8CAE-F5A6FC7A8DD1Q24240451-CFDBBE70-3A8B-4F15-B5E3-6351F52ABD51Q24245204-0B85169E-C579-4D94-9219-27A0F35AD7D6Q24245531-A671ED9E-55E3-40F5-A43E-988B428AF865Q28073307-BEE42EF5-2A1A-41C2-A52C-62933676EE01Q28194923-928D1CD7-D30F-4EAA-AD72-ED6BD0CEFCA6Q30448910-73CC645B-5AF6-4219-8258-CA532421BB80Q30833127-F7EA369E-7E5F-457C-8713-60C8D2CF9967Q30883837-4FFD2A64-DAEC-4F5C-92DE-0B974B5E6351Q33312414-C276FCA1-B643-4AB3-AD21-E75DEE4BA9EDQ33335930-F926565B-BABE-4EB8-8C46-E70A597CE535Q33876266-A4EEFE6B-A918-43E0-95C2-D89C3719D92DQ33894276-01CDE427-C144-466C-9F9C-FEBE03880D18Q34272848-1E136314-64CA-4C0A-80BB-17F07FCACB36Q34472516-C051185B-9310-433F-BF27-A3BFF4A4ED9AQ34786006-1C73A826-C638-419E-9B34-17D12C5986DAQ35578941-69E74967-461A-4F14-810E-9F976CDF89EAQ36077574-308C98D9-0395-48D7-A82F-5593DABB2EF1Q36088143-9FC259BB-AD7A-4DD3-ACE4-D6AAB65D1F5BQ36142617-87FD0447-D5D8-4DA0-9EED-F0E015A37294Q36150578-24602ADB-1A76-4243-83ED-9F09A3D53D14Q36284647-667EE4D7-1771-417F-A325-0A4A9CEA42E4Q36313315-3C906BA1-6770-4601-A3D4-6E8B0B757C07Q36349573-71109D58-F598-45AE-8452-8C0F64E1BD67Q36349585-96F5FEE7-7092-43C3-A342-B80D5016D675Q36399906-166E34F3-8D85-4BEB-AC0A-F9E8CF67C4E7Q36537350-EBA6121D-BB17-4C12-8221-B5C7A227A770Q36793211-93099A37-FA76-4FD9-B0E6-65FBA580E005Q36800526-DA37EC28-FE88-4495-AFE8-B5AC699C535DQ36944012-E14FA47B-0CE6-4AD3-B1F4-9F9C93763774Q36950625-6AECB66D-A1A4-4FB6-B926-0BA6FD0B941FQ36972704-BEC27B6A-CDB6-4DEF-B0F8-AB07E5496316Q37117872-5922DF7F-1632-4931-A6C3-79C007329FADQ37147203-B915792A-CE00-47DE-93D9-6FFA621BB83AQ37179642-AB74112D-FEC0-4499-AC9A-2087A7F3DDB5Q37691716-E520DA93-A3F1-4F36-859A-1C467402372DQ38035818-992B747D-6314-4D42-8BEA-7DD6BA9D4D0FQ38683464-B62B8EC2-1400-4F62-9251-7E44873E2D30Q38762498-5F0E084B-E315-45C3-9CA3-FEADC45DE364
P2860
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
@en
type
label
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
@en
prefLabel
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
@en
P2093
P1433
P1476
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage
@en
P2093
Brett E Skolnick
Europe/AustralAsia NovoSeven ICH Trial Investigators
Joseph Broderick
Nikolai C Brun
Stephan A Mayer
Stephen Davis
Thorsten Steiner
P356
10.1161/01.STR.0000149628.80251.B8
P407
P577
2004-11-29T00:00:00Z